For the majority of the experts (77.8%), difficulties in laboratory monitoring did have somewhat of an impact (44.4%) or was a real obstacle (33.3%) affecting their treatment decision when choosing prophylaxis for a person with hemophilia A. Next, the experts were asked about their clinical observations when introducing/switching a person with hemophilia to an EHL product, e.g., recombinant FVIII Fc fusion protein (rFVIIIFc), from a standard half-life (SHL) (pdFVIII or rFVIII) product (Figure 1). The gene discussed is F8; the disease is hemophilia.